Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New trial aims to cut opioid use in pancreatic cancer with early nerve block

NCT ID NCT06160323

Symptom relief Sponsor: Chinese University of Hong Kong Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving a nerve block early, rather than waiting, can better control pain in people with inoperable pancreatic cancer. The procedure uses an endoscope to inject numbing medication near nerves that carry pain signals. Researchers will compare pain scores and opioid use between the early nerve block group and those who follow standard step-up pain management.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
EUS-guided celiac ganglion neurolysis (nerve block procedure)
What this could lead to
If it works, this could offer a more effective way to control severe pain in pancreatic cancer patients, reducing reliance on strong opioids and their side effects.
What could go wrong
This is a relatively small trial (94 people) and the procedure carries risks like bleeding or nerve damage. It may not prove better than standard care, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 94 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2023

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age \>= 18 years old 2. Diagnosed to have inoperable pancreatic cancer 3. Presence of tumor pain (centrally located, constant, with no other obvious cause) with a VAS \>= 3 4. Karnofsky performance status \>= 60 5. Planned for EUS examination and/or biopsy of the pancreatic tumor Exclusion Criteria: 1. Allergy to bupivacaine, or alcohol 2. Potentially operable after neoadjuvant therapy 3. Expected survival of less than 3 months 4. Patient who is already on opioids for pain control 5. Previous percutaneous or EUS-guided CGN/ CPN 6. Recurrent pancreatic tumors after operation 7. Uncorrectable coagulopathy 8. Inability or unwillingness to provide informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pain cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cancer Pain exocrine pancreatic carcinoma malignant pancreatic neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pain cancer Pancreatic cancer non-resectable Tumor pancreas

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Prince of Wales Hospital

    RECRUITING

    Hong Kong, Hong Kong, 00000, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.